drug

Brilaroxazine

RP5063
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Reviva Pharmaceuticals
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335Phase 3Recruiting
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
NCT01490086Phase 2Completed

KOLs & investigators

1
M Cantillon

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Reviva Pharmaceuticals
company
trial
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
PHASE3
trial
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Acute Schizophrenia
indication
Psychotic Disorders
indication
KOL
M Cantillon
KOL score —
person